Associated Papers
Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review.
Chanhih N et al.
International Journal of Molecular Sciences, 2025
41303533 (PubMed )
Supplement: ijms-26-11049-s001.zip › Supp_M_Table_S7.pdf
Quantitative thresholds for variant enrichment in 13,845 cases: improving pathogenicity classification in genetic hearing loss.
Liu S et al.
Genome Medicine, 2023
38111038 (PubMed )
Supplement: 13073_2023_1271_MOESM1_ESM.xlsx › Table_S6
Plasma Circulating Tumor DNA Sequencing Predicts Minimal Residual Disease in Resectable Esophageal Squamous Cell Carcinoma.
Liu T et al.
Frontiers in Oncology, 2021
34094900 (PubMed )
Supplement: DataSheet_1.xlsx › Table_S6
Spectrum of Mesenchymal-Epithelial Transition Aberrations and Potential Clinical Implications: Insights From Integrative Pancancer Analysis.
Li J et al.
Frontiers in Oncology, 2020
33178590 (PubMed )
Supplement: Table_2.XLSX › ___1
The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma.
Hong S et al.
Nature Communications, 2019
31311932 (PubMed )
Supplement: 41467_2019_10902_MOESM8_ESM.xlsx › Sheet1
Gastrointestinal malignancies harbor actionable MET exon 14 deletions.
Lee J et al.
Oncotarget, 2015
26375439 (PubMed )
Supplement: oncotarget-06-28211-s003.xlsx › Cosmic_MET
Select a paper to view details